Molecular mechanism of methotrexate action in inflammation

Inflammation

Volumn 16, Issue 5, 1992, Pages 411-423

  Cronstein, Bruce N ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

BIOCHEMISTRY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; CELLS; HUMAN; INFLAMMATION; METHOTREXATE; METHYLATION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026709899     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/BF00918968     Document Type: Review

References (98)

1. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis; 84-month update
2. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis; update after a mean of 90 months
3. Efficacy of low-dose methotrexate in rheumatoid arthritis
4. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: A controlled clinical trial
5. Weekly pulse methotrexate in rheumatoid arthritis: Clinical and immunologic effects in a randomized double-blind study
6. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
7. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: A twenty-four-week controlled clinical trial
8. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis: A randomized, double blind 26-week trial
9. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (myochrisine) in the treatment of rheumatoid arthritis
10. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis: A thirty-six-week, double-blind trial
11. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
12. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis
13. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: Toxicity, efficacy and radiological progression
14. Methotrexate in rheumatoid arthritis: Effects on disease activity in a multicenter prospective study
15. Advances in drug therapy for inflammatory bowel disease
16. Long-term methotrexate treatment in corticosteroid-dependent asthma
17. Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study
18. Methotrexate in the treatment of steroid-dependent asthma
19. Use of methotrexate in the treatment of steroid-dependent adolescent asthmatics
20. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study
21. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma
22. Effect of medication on synovial leukocyte differentials in patients wil:h rheumatoid arthritis
23. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs
24. The effect of methotrexate and hydroxyurea on neutrophil chemotaxis
25. Effect of methotrexate on phagocytosis and killing of Staphylococcus aureus and human granulocytes
26. Monocyte and neutrophil chemotaxis in psoriasis. Clinical and experimental studies
27. Neutrophil and monocyte chemotaxis in methotrexatetreated psoriasis patients
28. Inhibition of leukotriene B4 synthesis in neutrophils from patients with Rheumatoid Arthritis by a single oral dose of methotrexate
29. The effects of some anti-arthritic drugs and cytokines on the shape and function of rodent macrophages
30. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis
31. Effect of anticancer drags on macrophage-mediated antibody-dependent cytotoxicity and secretion of reactive oxygen intermediates
32. Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis
33. Studies on the effect of methotrexate on macrophage function
34. The effect of low dose chronic intermittent parenteral methotrexate on delayed type hypersensitivity and acute inflammation in a mouse model
35. Measures of immunologic and inflammatory responses in vitro in rheumatoid patients treated with methotrexate
36. The influence of methotrexate and thymidineon the human natural killer cell function in vitro
37. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells
38. Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition by purine biosynthesis as a major mechanism of action
39. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects
40. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis
41. Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study
42. Studies on the effect of low dose methotrexate on rat adjuvant arthritis
43. Inhibition of in vitro vascular endothelial proliferation and in vivo neovascularization by low-dose methotrexate
44. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis
45. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis
46. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients
47. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy: Double-blind study
48. Polyglutamation of methotrexate. Is methotrexate a prodrug?
49. Pharmacokinetics of the polygamma-glutamyl metabolites of methotrexate in skin and other tissues of rats and hairless mice
50. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates
51. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate
52. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide
53. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: Effects on flow, granulocytes and injury
54. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells
55. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils
56. Suppression of human polymorphonuclear leukocyte phagocytosis by adenosine analogs
57. Methylxanthine bronchodilators potentiate multiple human neutrophil functions
58. Endogenous and exogenous adenosine inhibit granulocyte aggregation without altering the associated rise in intracellular calcium concentration
59. 2-Chloroadenosine inhibits complement-induced reactive oxygen metabolite production and recovery of human polymorphonuclear leukocytes attacked by complement
60. The adenosine/neutrophil paradox resolved. Human neutrophils possess both A1 and A2 receptors which promote chemotaxis and inhibit O2-generation, respectively
61. Occupancy of adenosine receptors on human neutrophils inhibits the respiratory burst stimulated by ingestion of complement coated particles and occupancy of chemoattractant but not Fc receptors
62. Adenosine regulates the respiratory burst of cytokine-triggered human neutrophils adherent to biologic surfaces
63. Effects of adenosine on polymorphonuclear leucocyte function, cyclic 3′∶ 5′-adenosine monophosphate, and intracellular calcium
64. Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells
65. Adenosine receptors on human lymphocytes
66. Lymphocyte membrane adenosine receptors coupled to adenylate cyclase; properties and occurrence in various lymphocyte subclasses
67. Impaired immunoregulation in systemic lupus erythematosus: Defective adenosine-induced suppressor T lymphocyte generation
68. Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus
69. Adenosine A2 receptors on human monocytes modulate C2 production
70. Regulation of macrophage lysosomal secretion by adenosine, adenosine phosphate esters, and related structural analogues of adenosine
71. Adenosine receptors on rabbit alveolar macrophages: Binding characteristics and effects on cellular function
72. Characterization of a specific adenosine receptor on human lymphocytes
73. Potentiation of mast cell mediator release by adenosine
74. Adenosine receptors on mouse bone marrow-derived mast cells: Functional significance and regulation by amino-phylline
75. The antiinflammatory effects of adenosine receptor agonists on the carrageenan-induced pleural inflammatory response in rats
76. Selective adenosine release from human B but not T lymphoid cell line
77. Adenosine; a physiologic modulator of Superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils
78. The effects of adenosine agonists on human neutrophil function
79. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization
80. Inhibition by adenosine of reactive oxygen metabolite production by human polymorphonuclear leucocytes
81. Adenosine receptors are expressed during differentiation of monocytes to macrophages in vitro
82. Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy: A1 receptors are stimulatory and A2 receptors are inhibitory
83. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine
84. Transmethylation reactions regulate affinity and functional activity of chemotactic factor receptors on macrophages
85. Biochemical perturbations of BW 91Y (3-deazaadenosine) on human neutrophil chemotactic potential and lipid metabolism
86. 3-Deazaadenosine-induced disorganization of macrophage microfilaments
87. 3-Deazaadenosine 5′-triphosphate: A novel metabolite of 3-deazaadenosine in mouse leukocytes
88. The action of the adenosylhomocysteine hycrolase inhibitor, 3-deazaadenosine, on phagocytic function of mouse macrophages and human monocytes
89. Regulatory role for the immune complex in modulation of phagocytosis by 3-deazaadenoshe
90. 3-Deaza-adenosine inhibition of stimulus-response coupling in human polymorphonuclear leukocytes
91. 3-deazaadenosine inhibits leukocyte adhesion and ICAM-1 biosynthesis in tumor necrosis factor-stimulated human endothelial cells
92. Inhibition of lymphocyte-mediated cytolysis by 3-deazaadenosine: Evidence for a methylation reaction essential for cytolysis
93. Irnidazo [4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents
94. Paradoxical effects of adenosine on neutrophil chemotaxis
95. Inhibition of macrophage phagocytosis by methylation inhibitors: Lack of correlation of protein carboxymethylation and phospholipid methylation with phagocytosis
96. 3-Deazaadenosine. S-adenosylhomocysteine hydrolase-independent mechanism of action in mouse lymphocytes